BioCryst Pharmaceuticals, Inc.
BCRXHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned May 30, 2026
Scan Results
Daily timeframeBioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. At a $2.26B market cap, BioCryst Pharmaceuticals, Inc. ranks as a mid-cap company within healthcare. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Market Cap
$2.26B
Beta
0.57
P/E (TTM)
—
P/E (Fwd)
13.10
EPS (TTM)
$-1.77
EPS (Fwd)
$0.68
ROE
—
ROA
42.6%
Cash
$238.4M
Total Debt
$858.1M
Free CF
$264.4M
52W Change
-17.0%
Annual Financials
Cash vs Debt
On the balance sheet, BCRX has $238.4M in cash with $858.1M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $264.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on assets of 42.6% further supports the picture of efficient asset utilization. Revenue has grown from $270.8M (2022) to $874.8M (2025), reflecting a 223% increase over the period.
The relatively low beta of 0.57 suggests BCRX is a less volatile holding compared to the broader index. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BCRX.